Irvine-based Allergan Inc. on Friday appointed F. Michael Ball as its president, succeeding David Pyott, who retains his chief executive and chairman titles.
Ball, who has been with Allergan since 1995, has been the drug maker’s executive vice president of pharmaceuticals since 2003.
In that role, Allergan said Ball has been responsible for the reorganization and management of the company’s global commercial operations.
His task now: melding Santa Barbara-based Inamed Corp. into Allergan.
The drug maker is buying Inamed for $3.2 billion in a deal set to close in coming weeks.
“In his new role, Mike will take on responsibility for the integration of Inamed as well as continuing to drive focus within our specialty franchises to further increase our overall growth and profitability,” Pyott said in a release.
Allergan is awaiting word from the Federal Trade Commission on its offer to buy Inamed, which makes breast implants, obesity treatments and dermal fillers.
